Elanco Animal Health (ELAN) Scheduled to Post Earnings on Thursday

Elanco Animal Health (NYSE:ELAN) will release its earnings data before the market opens on Thursday, November 7th. Analysts expect Elanco Animal Health to post earnings of $0.12 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the prior year, the business posted $0.18 EPS. The company’s quarterly revenue was up 12.0% on a year-over-year basis. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Trading Up 2.1 %

Elanco Animal Health stock opened at $12.77 on Thursday. The firm has a 50-day moving average of $14.19 and a 200-day moving average of $14.75. Elanco Animal Health has a one year low of $8.59 and a one year high of $18.80. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. The company has a market cap of $6.31 billion, a price-to-earnings ratio of -4.82, a P/E/G ratio of 1.32 and a beta of 1.40.

Insider Activity at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons bought 100,000 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were purchased at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the purchase, the chief executive officer now owns 145,000 shares in the company, valued at $1,886,450. This represents a 200.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Jeffrey N. Simmons purchased 100,000 shares of the business’s stock in a transaction on Monday, August 12th. The shares were acquired at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. The trade was a 200.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were purchased at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the transaction, the director now directly owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ELAN has been the subject of several recent analyst reports. Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. Finally, Barclays lowered their price target on shares of Elanco Animal Health from $22.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.